Navigation Links
Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine
Date:6/11/2008

s necessary to conduct additional clinical trials or to market any product for travelers' diarrhea; that estimates of market size overstate the number of travelers who would use such a product, if it were approved; that competitors may develop products that are safer, more effective, or more convenient to use; that the proposed acquisition of Iomai by Intercell does not close or that the companies may be required to modify aspects of the transaction to achieve regulatory approval; that prior to the closing of the acquisition, Iomai's business suffers due to uncertainty; that the companies are unable to successfully execute their integration strategies, or achieve planned synergies; and the risks identified under the heading "Factors That May Impact Future Results" in Management's Discussion and Analysis of Financial Condition and Results of Operations in Iomai's Quarterly Report on Form 10-Q for the three months ended March 31, 2008, and filed with the Securities and Exchange Commission. Iomai cautions investors and others not to place undue reliance on the forward-looking statements contained in this press release. Iomai's business is subject to many risks. For a discussion of such risks, you are encouraged to read the documents the Company files with the U.S. Securities and Exchange Commission, available at http://www.sec.gov. The statements in this press release speak only as of the date of this document.

About Intercell AG

Intercell AG is a growing biotechnology company which focuses on the design and development of novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical need. The Company develops antigens and adjuvants which are derived from its proprietary technology platforms and has in-house GMP manufacturing capabilities. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novart
'/>"/>

SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
3. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
4. Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5
5. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
6. Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
7. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015  Oncobiologics, Inc., a biotherapeutics company ... biosimilars, has completed the construction of its GMP ... Cranbury, New Jersey . ... is designed to utilize multiple technologies that enable ... Through the use of the latest single-use technologies, ...
(Date:5/4/2015)... May 4, 2015   HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of advanced ... Godshall , is scheduled to present at the Bank of ... Las Vegas on Thursday, May 14, 2015, at ... webcast of the Company,s presentation at the conference will be ...
(Date:5/4/2015)... May 4, 2015  CytRx Corporation (Nasdaq: ... specializing in oncology, today announced an interim analysis ... studies pairing aldoxorubicin with either gemcitabine or ifosfamide. ... ifosfamide with escalating doses of aldoxorubicin. The combinations ... the lowest dose level of aldoxorubicin (170 mg/m2), ...
Breaking Medicine Technology:Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7
... SUNNYVALE, Calif., Dec. 22 Arrayit Corporation (OTC Bulletin Board: ... that the Company has made a technological breakthrough in the ... which are tiny glass substrates that contain rows and columns ... The advance allows highly precise printing of as many as ...
... , NEW YORK, Dec. 22 Delcath Systems, Inc. (Nasdaq: ... treatment method for primary and metastatic cancers to the liver, ... Scientific Advisory Board, effective immediately. , "We formed our ... our Delcath PHP System(TM) with insight from the leading experts ...
Cached Medicine Technology:Arrayit Corporation Announces Manufacturing Breakthrough 2Arrayit Corporation Announces Manufacturing Breakthrough 3Professor Riccardo Lencioni Joins Delcath Systems' Scientific Advisory Board 2Professor Riccardo Lencioni Joins Delcath Systems' Scientific Advisory Board 3
(Date:5/4/2015)... 04, 2015 Leonardo J. Lozada, M.D., ... physician executive, and William C. Daniel, M.D., Saint Luke’s ... personal invitations from the Secretary of the Air Force ... at the Air War College, Maxwell Air Force Base, ... citizens to senior U.S. and international officers and their ...
(Date:5/4/2015)... Pa. (PRWEB) May 04, 2015 Milton ... ’87, the 2015 Alumnus of the Year, recognizing his ... excellence and philanthropy he sets for MHS students. , ... that can happen when children are provided a top-notch ... and hone their passions,” said Pete Gurt ’85, president ...
(Date:5/4/2015)... York, NY (PRWEB) May 04, 2015 ... specialized insurance programs, announces the expansion of coverage for ... is a leading provider of industry-tailored insurance and proactive ... McNeil & Company, we are dedicated to providing our ... to meet their many evolving needs. We are excited ...
(Date:5/4/2015)... “ LiveSchool ” was featured on ... a look at the latest and coolest applications on ... the host of AppWatch and technology expert, conducted the ... allows teachers to reward students with good behavior. , ... in the classroom. And the good people at ...
(Date:5/4/2015)... May 04, 2015 The American Telemedicine ... state policy reports which identify gaps in coverage and ... ATA issued the State Telemedicine Gaps Reports last September, ... their laws and regulations impact healthcare delivery in their ... result of state actions across the nation, ATA reevaluated ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:Milton Hershey School Names 2015 Alumnus of the Year 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3
... year saga of HIV Positive patient Shenequa Flucas is an ... hold the key to curb its escalation. // ,She ... second baby. Depressed with low self esteem, she is ... she received, that opened her mind rather than closing it. ...
... of beauty are most commonly blamed for lowering self-esteem ... trend, // a lot of marketing companies (including Dove) ... messages in an effective way. ,A new ... more likely to lower the onlooker’s self esteem, contrary ...
... study has highlighted that women exposed to high levels of ... than those who have a smooth sail through life. The ... that evaluated the stress levels of women between 1994 and ... were more likely to die over the next 8 years. ...
... Drugs meant for treatment of Attention Deficit Hyperactivity Disorder ... be subjected to stringent clinical trials to assess the ... ,The decision has been taken following the reports ... warnings should be associated with marketing of such drugs. ...
... of fluid filled plastic teething ring, manufactured by The ... been urged by the Food and Drug Administration to ... ,The contaminated liquid if swallowed or absorbed through ... sickness. Malnourished infants, infants with compromised immune function or ...
... (NY) and Catholic University of America in Washington, D.C. ... between themselves affects the emotional development of the// children. ... the psyche of their children is detailed in the ... ,"A useful analogy is to think about emotional security ...
Cached Medicine News:Health News:Parental Conflicts Lead To Emotional Insecurity In Children 2
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
The AMY method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of amylase activity in serum, plasma and urine....
Enzymatic Clearance assay for the in vitro quantitative determination of LDL-cholesterol in human serum and plasma....
Medicine Products: